Mapping α2 Adrenoceptors of the Human Brain with 11C-Yohimbine

A previous study from this laboratory suggested that 11C-yohimbine, a selective α2-adrenoceptor antagonist, is an appropriate ligand for PET of α2 adrenoceptors that passes readily from blood to brain tissue in pigs but not in rodents. To test usefulness in humans, we determined blood–brain clearances, volumes of distribution, and receptor availability by means of PET with 11C-yohimbine in healthy male adults. Methods: We recorded the distribution of 11C-yohimbine with 90-min dynamic PET and sampled arterial blood to measure intact 11C-yohimbine in plasma. For analysis, we coregistered PET images to individual MR images and automatically identified 27 volumes of interest. We used 1-tissue-compartment graphical analysis with 6 linearized solutions of the fundamental binding equation, with the metabolite-corrected arterial plasma curves as input function, to estimate the kinetic parameters of 11C-yohimbine. With the lowest steady-state distribution volume (VT), determined in the corpus callosum, we calculated the binding potential (receptor availability) of the radioligand in other regions. Results: The linear regressions yielded similar estimates of the kinetic parameters. The cortical values of VT ranged from 0.82 mL cm−3 in the right frontal cortex to 0.46 mL cm−3 in the corpus callosum, with intermediate VT values in subcortical structures. Binding potentials averaged 0.6–0.8 in the cortex and 0.2–0.5 in subcortical regions. Conclusion: The maps of 11C-yohimbine binding to α2 adrenoceptors in human brain had the highest values in cortical areas and hippocampus, with moderate values in subcortical structures, as found also in vitro. The results confirm the usefulness of the tracer 11C-yohimbine for mapping α2 adrenoceptors in human brain in vivo.

[1]  A. Gjedde,et al.  Neurokinetics: The Dynamics of Neurobiology in Vivo , 2014 .

[2]  Richard E. Carson,et al.  Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo , 2010, Biological Psychiatry.

[3]  A. Gjedde,et al.  Inverted-U-shaped correlation between dopamine receptor availability in striatum and sensation seeking , 2010, Proceedings of the National Academy of Sciences.

[4]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  S. Jakobsen,et al.  Detection of alpha-2 adrenergic receptors in brain of living pig with [11C]yohimbine , 2006, NeuroImage.

[6]  M. Bakker,et al.  Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist. , 2006, Bioorganic & medicinal chemistry.

[7]  L. Minuzzi,et al.  Inhibition of [11C]mirtazapine binding by α2‐adrenoceptor antagonists studied by positron emission tomography in living porcine brain , 2006, Synapse.

[8]  A. Rosenquist,et al.  Noradrenergic mechanisms in neurodegenerative diseases: a theory , 2004, Brain Research Reviews.

[9]  John Duncan,et al.  Implementation and application of a brain template for multiple volumes of interest , 2002, Human brain mapping.

[10]  K. Starke Presynaptic autoreceptors in the third decade: focus on α2‐adrenoceptors , 2001 .

[11]  A. Gjedde,et al.  Basic CNS Drug Transport and Binding Kinetics In Vivo , 2000 .

[12]  David J. Begley,et al.  The Blood-brain Barrier and Drug Delivery to the CNS , 2000 .

[13]  J. Melichar,et al.  Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central α2-adrenoceptors , 2000, European Journal of Nuclear Medicine.

[14]  R. Le Verge,et al.  Biopharmaceutics and metabolism of yohimbine in humans. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  A. Gjedde,et al.  Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  M. Berlan,et al.  α2‐Adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine , 1993, British journal of pharmacology.

[17]  M. Scheinin,et al.  Differential expression of two α2-adrenergic receptor subtype mRNAs in human tissues , 1992 .

[18]  D. Bylund Subtypes of alpha-1 and alpha-2 adrenergic receptors , 1992, European Neuropsychopharmacology.

[19]  Á. Pazos,et al.  Quantitative light microscopic autoradiographic localization of α 2-adrenoceptors in the human brain , 1992, Brain Research.

[20]  T. Branchek,et al.  Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor. , 1990, Molecular pharmacology.

[21]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  A. Gjedde,et al.  Blood—Brain Transfer and Metabolism of 6-[18F]Fluoro-L-DOPA in Rat , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  M. Caron,et al.  Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Caron,et al.  Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor. , 1987, Science.

[25]  Albert Gjedde,et al.  Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination , 1982, Brain Research Reviews.

[26]  A. Gjedde,et al.  Analysis of Neuroreceptor Binding In Vivo , 2011 .

[27]  Albert Gjedde,et al.  Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. , 2005, International review of neurobiology.

[28]  E. Peskind,et al.  Cerebrospinal fluid and plasma disposition of yohimbine and 11-hydroxy-yohimbine in young and older healthy subjects, and Alzheimer's disease patients , 1997, European Journal of Clinical Pharmacology.